Advertisement

Archives of Virology

, Volume 163, Issue 8, pp 2111–2119 | Cite as

Surveillance of HIV-1 drug resistance in Xinjiang: high prevalence of K103N in treatment-naïve individuals

  • Zhanjun Shu
  • Yuying Chen
  • Aihemaiti Abudureyimu
  • Tingting Li
  • Ting Yuan
  • Jianping Ma
  • Xiaochun Li
  • Xiulan Ma
  • Chengyuan Jang
  • Gang Bao
  • Binlian Sun
  • Rongge Yang
Original Article

Abstract

To identify transmitted and acquired HIV-1 drug resistance mutations in Xinjiang, China, we collected the peripheral blood of 50 treated and 50 treatment-naïve HIV-1-infected individuals in this region. We successfully amplified 36 reverse transcriptase and 42 protease gene sequences of HIV-1 from 51 individuals and identified mutations associated with resistance to reverse transcriptase (RT) and protease (PR) inhibitors (RTIs and PIs) according to Stanford Drug Resistance Database. Among the drug-treated individuals, the results showed that K103N in the RT region was the most frequent mutation, found in 67% (6/9) of the cases, followed by M184V with 56% (5/9). Five individuals had both nucleoside and non-nucleoside reverse transcriptase inhibitor resistance mutations after more than 12 months of treatment. Among the untreated individuals, 33% (9/27) were found to harbor drug resistance mutations in the RT gene. K103N occurred at the highest rate, accounting for 22% (6/27), followed by P225H (7%) and Y188L (4%). Neither of the two groups showed any major resistance mutations to PIs. Our study revealed that the prevalence of drug resistance was relatively high in Xinjiang and that K103N occurred at the highest rate. These results suggest that it is important to carry out HIV drug resistance testing, especially for the K103N mutation in the RT region, before and during the treatment process. This study may help to guide ART strategies in the Xinjiang region.

Notes

Acknowledgements

The authors would like to thank the Key Laboratory on Emerging Infectious Diseases and Biosafety in Wuhan and The Core Facility and Technical Support, Wuhan Institute of Virology.

Author contributions

ZS, YC, TL, BS, RY and conceived and designed the experiments; AA, JM, XL, XM, CJ and GB collected the samples; YC, TL and TY performed the experiments; YC analyzed the data; ZS, YC, BS and RY wrote and edited the paper. All authors have read and approved the final manuscript.

Funding

This study was supported by Grant 201409 from Construction Project of Clinical Service Ability for Prevention and Treatment of Major and Difficult Diseases of State Administration of Traditional Chinese Medicine, Grant JDZX2015238 from Special Scientific Research of Bases for TCM Clinical Research of State Administration of Traditional Chinese Medicine, and Grant 2016YFC1202800 from the National Key Research Projects of China.

Compliance with ethical standards

Conflict of interest

The authors of the current study declare no conflict(s) of interest.

Ethical approval

The study was approved by the Ethics Committees of the Sixth People’s Hospital of Xinjiang Uygur Autonomous Region and Wuhan Institute of Virology.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Accession numbers

The accession numbers of the sequences analyzed in this study are MF325036-MF325086.

References

  1. 1.
    Aghokeng AF, Monleau M, Eymard-Duvernay S, Dagnra A, Kania D, Ngo-Giang-Huong N, Toni TD, Touré-Kane C, Truong LX, Delaporte E (2013) Extraordinary heterogeneity of virological outcomes in patients receiving highly antiretroviral therapy and monitored with the World Health Organization public health approach in sub-saharan Africa and southeast Asia. Clin Infect Dis 58:99–109CrossRefPubMedGoogle Scholar
  2. 2.
    AIDS Professional Group, Society of Infection Diseases CMA (2016) Forth edition of the guidelines for diagnosis and treatment of HIV/AIDSGoogle Scholar
  3. 3.
    Barth RE, van der Loeff MFS, Schuurman R, Hoepelman AI, Wensing AM (2010) Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis 10:155–166CrossRefPubMedGoogle Scholar
  4. 4.
    Clavel F, Hance AJ (2004) HIV drug resistance. N Engl J Med 350:1023–1035CrossRefPubMedGoogle Scholar
  5. 5.
    Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH (2016) Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med 375:830–839CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Guo J, Yan Y, Zhang J, Ji J, Ge Z, Ge R, Zhang X, Wang H, Chen Z, Luo J (2017) Genetic characterization and antiretroviral resistance mutations among treatment-naive HIV-infected individuals in Jiaxing, China. Oncotarget 8:18271PubMedPubMedCentralGoogle Scholar
  7. 7.
    Dong Y, Wang L, He C, Zuo H, Wang F, Liao L, Guan X, Liu W, Zhao J, Xing H (2015) Research on HIV subtype and drug resistance transmission in Xinjiang in 2010–2013. Chin J AIDS STD 1:20–23Google Scholar
  8. 8.
    Hao M, Wang J, Xin R, Li X, Hao Y, Chen J, Ye J, Wang Y, He X, Huang C (2017) Low rates of transmitted drug resistances among treatment-naive HIV-1-infected students in Beijing, China. AIDS Res Hum Retrovir 33:970–976CrossRefPubMedGoogle Scholar
  9. 9.
    Ni J, Chen J, Zhang Y, Jin T, Wang F, Hu X, Dong Y (2012) Analysis of epidemic status of HIV/AIDS in Xinjiang. Bull Dis Control Prev 27(2):1–3Google Scholar
  10. 10.
    Zuo H, Liao L, Sun L, Zhang Y, Xing H (2016) Survey on transmitted HIV-1 drug resistance in Urumqi, Xinjiang in 2014. Chin J AIDS STD 22:586–588Google Scholar
  11. 11.
    Li J (2010) HIV-1 drug resistance mutations. Chin J AIDS STD 2:195–200Google Scholar
  12. 12.
    Li L, Sun B, Zeng H, Sun Z, Sun G, Yang R (2014) Relatively high prevalence of drug resistance among antiretroviral-naive patients from Henan, Central China. AIDS Res Hum Retrovir 30:160–164CrossRefPubMedGoogle Scholar
  13. 13.
    Li T, Qian F, Yuan T, Xu W, Zhu L, Huang J, Wang H, Zhu Y, Wang Y, Li X (2017) Drug resistance mutation profiles of the drug-naïve and first-line regimen-treated HIV-1-infected population of Suzhou, China. Virol Sin 32:271–279CrossRefPubMedGoogle Scholar
  14. 14.
    Liao L, Xing H, Shang H, Li J, Zhong P, Cheng H, Li X (1999) Shao Y (2010) The prevalence of transmitted antiretroviral drug resistance in treatment naïve HIV-infected individuals in China. J Acquir Immune Defic Syndr 53:S10CrossRefGoogle Scholar
  15. 15.
    Liu C, Sun D, Sun G, Liu J, Zhu Q, Tian S, Yang W, Xue X, Wu Y, Wang Z (2015) Population-based human immunodeficiency virus 1 drug resistance profiles among individuals who experienced virological failure to first-line antiretroviral therapy in Henan, China during 2010–2011. AIDS Res Ther 12:22CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Luo M, Liu H, Zhuang K, Liu L, Su B, Yang R, Tien P, Zhang L, Gui X, Chen Z (2009) Prevalence of drug resistant HIV-1 in rural areas of Hubei province in the People’s Republic of China. J Acquir Immune Defic Syndr (1999) 50:1CrossRefPubMedCentralGoogle Scholar
  17. 17.
    National H (2015) 2015 China AIDS Response Progress Report. http://www.unaids.org.cn/en/index/index.asp
  18. 18.
    Rhee S-Y, Blanco JL, Jordan MR, Taylor J, Lemey P, Varghese V, Hamers RL, Bertagnolio S, de Wit TFR, Aghokeng AF (2015) Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient-and sequence-level meta-analysis. PLoS Med 12:e1001810CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Stadeli KM, Richman DD (2013) Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review. Antivir Ther 18:115CrossRefPubMedGoogle Scholar
  20. 20.
    Tamura K, Stecher G, Peterson D, Filipski A, Kumar S (2013) MEGA6: molecular evolutionary genetics analysis version 6.0. Mol Biol Evol 30:2725–2729CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    van de Vijver DA, Wensing AM, Angarano G, Åsjö B, Balotta C, Boeri E, Camacho R, Chaix M-L, Costagliola D, De Luca A (2006) The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. JAIDS J Acquir Immune Defic Syndr 41:352–360CrossRefPubMedGoogle Scholar
  22. 22.
    Wainberg MA, Brenner BG, Turner D (2005) Changing patterns in the selection of viral mutations among patients receiving nucleoside and nucleotide drug combinations directed against human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 49:1671–1678CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Wang F, Tao J, Hu X, Ni M (2015) Research of drug-resistance of patients with HIV-1 in Ili Prefecture, Xinjiang. Bull Dis Control Prev 30:4–6Google Scholar
  24. 24.
    Wang Y, Xing H, Liao L, Wang Z, Su B, Zhao Q, Feng Y, Ma P, Liu J, Wu J (2014) The development of drug resistance mutations K103N Y181C and G190A in long term Nevirapine-containing antiviral therapy. AIDS Res Ther 11:36CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Weng Y-W, Tsai H-C, Lee SS-J, Wu K-S, Sy C-L, Chen J-K, Chen Y-S (2016) Prevalence and associated factors for HIV-1 transmitted drug resistance in voluntary clients for counseling and testing in Southern Taiwan. J Microbiol Immunol Infect 49:487–493CrossRefPubMedGoogle Scholar
  26. 26.
    Wittkop L, Günthard HF, De Wolf F, Dunn D, Cozzi-Lepri A, De Luca A, Kücherer C, Obel N, Von Wyl V, Masquelier B (2011) Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis 11:363–371CrossRefPubMedGoogle Scholar
  27. 27.
    Xin R, He X, Xing H, Sun F, Ni M, Zhang Y, Meng Z, Feng Y, Liu S, Wei J (2009) Genetic and temporal dynamics of human immunodeficiency virus type 1 CRF07_BC in Xinjiang, China. J Gen Virol 90:1757–1761CrossRefPubMedGoogle Scholar
  28. 28.
    Zhang Y, Wang F, Jin T, Ni M (2014) Research on HIV-1 incidence among drug users and their partners in Xinjiang province between 2009 and 2011. Mod Prev Med 6:1105–1107Google Scholar

Copyright information

© Springer-Verlag GmbH Austria, part of Springer Nature 2018

Authors and Affiliations

  • Zhanjun Shu
    • 1
    • 4
  • Yuying Chen
    • 2
    • 3
  • Aihemaiti Abudureyimu
    • 1
  • Tingting Li
    • 2
    • 3
  • Ting Yuan
    • 2
  • Jianping Ma
    • 1
  • Xiaochun Li
    • 4
  • Xiulan Ma
    • 1
  • Chengyuan Jang
    • 4
  • Gang Bao
    • 4
  • Binlian Sun
    • 5
  • Rongge Yang
    • 2
  1. 1.The Fourth Affiliated Hospital of Xinjiang Medical UniversityÜrümqiPeople’s Republic of China
  2. 2.Research Group of HIV-1 Molecular Epidemiology and Virology, The State Key Laboratory of Virology, Wuhan Institute of VirologyChinese Academy of SciencesHubeiPeople’s Republic of China
  3. 3.University of Chinese Academy of SciencesBeijingPeople’s Republic of China
  4. 4.The Sixth People’s Hospital of Xinjiang Uygur Autonomous RegionÜrümqiPeople’s Republic of China
  5. 5.School of MedicineJianghan UniversityWuhanPeople’s Republic of China

Personalised recommendations